全文获取类型
收费全文 | 195篇 |
免费 | 10篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 35篇 |
妇产科学 | 3篇 |
基础医学 | 25篇 |
临床医学 | 7篇 |
内科学 | 36篇 |
皮肤病学 | 2篇 |
神经病学 | 4篇 |
特种医学 | 2篇 |
外科学 | 34篇 |
预防医学 | 8篇 |
药学 | 18篇 |
中国医学 | 12篇 |
肿瘤学 | 18篇 |
出版年
2022年 | 1篇 |
2021年 | 5篇 |
2019年 | 4篇 |
2018年 | 11篇 |
2017年 | 7篇 |
2016年 | 6篇 |
2015年 | 5篇 |
2014年 | 5篇 |
2013年 | 10篇 |
2012年 | 9篇 |
2011年 | 12篇 |
2010年 | 4篇 |
2009年 | 5篇 |
2008年 | 10篇 |
2007年 | 5篇 |
2006年 | 7篇 |
2005年 | 8篇 |
2004年 | 6篇 |
2003年 | 8篇 |
2002年 | 2篇 |
2001年 | 5篇 |
2000年 | 4篇 |
1999年 | 3篇 |
1997年 | 3篇 |
1996年 | 1篇 |
1994年 | 2篇 |
1993年 | 2篇 |
1992年 | 2篇 |
1991年 | 3篇 |
1990年 | 6篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 5篇 |
1986年 | 6篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1980年 | 2篇 |
1979年 | 10篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1975年 | 1篇 |
排序方式: 共有205条查询结果,搜索用时 0 毫秒
1.
Y. Le Meur M. Büchler A. Thierry S. Caillard F. Villemain S. Lavaud I. Etienne P.-F. Westeel B. H. de Ligny L. Rostaing E. Thervet J. C. Szelag J.-P. Rérolle A. Rousseau G. Touchard P. Marquet 《American journal of transplantation》2007,7(11):2496-2503
Efficacy and safety of mycophenolate mofetil (MMF) may be optimized with individualized doses based on therapeutic monitoring of its active metabolite, mycophenolic acid (MPA). In this 12-month study, 137 renal allograft recipients from 11 French centers receiving basiliximab, cyclosporine A, MMF and corticosteroids were randomized to receive either concentration-controlled doses or fixed-dose MMF. A novel Bayesian estimator of MPA AUC based on three-point sampling was used to individualize doses on posttransplant days 7 and 14 and months 1, 3 and 6. The primary endpoint was treatment failure (death, graft loss, acute rejection and MMF discontinuation). Data from 65 patients/group were analyzed. At month 12, the concentration-controlled group had fewer treatment failures (p = 0.03) and acute rejection episodes (p = 0.01) with no differences in adverse event frequency. The MMF dose was higher in the concentration-controlled group at day 14 (p < 0.0001), month 1 (p < 0.0001) and month 3 (p < 0.01), as were median AUCs on day 14 (33.7 vs. 27.1 mg*h/L; p = 0.0001) and at month 1 (45.0 vs. 30.9 mg*h/L; p < 0.0001). Therapeutic MPA monitoring using a limited sampling strategy can reduce the risk of treatment failure and acute rejection in renal allograft recipients 12 months posttransplant with no increase in adverse events. 相似文献
2.
Pernelle A Smits Laurel S Kleppe Tyra A Witt Cheri S Mueske Richard G Vile Robert D Simari 《Endothelium》2007,14(1):1-5
Cells with an endothelial phenotype can be cultured from peripheral blood. These cells include cells of a monocytic origin with endothelial features (culture-modified mononuclear cells, CMMCs) and, at later time points, blood outgrowth endothelial cells (BOECs). Both are promising candidates for systemic cell-based cardiovascular therapies and each may have unique capabilities. Indeed, the combined use of both cell types has been shown to have synergistic therapeutic features requiring simultaneous delivery. However, the majority of preclinical studies of cell delivery have used splenectomized animals to increase systemic distribution. The goal of this study was to directly compare the distribution of these two cell types following systemic delivery in an intact animal model. A similar pattern of delivery was seen following delivery of both cell types with detection in the lung, liver, bone marrow, and spleen. Taken together, the data suggest that strategies using systemic delivery of circulation-derived cells must consider the distribution and efficiency of delivery in intact animals. 相似文献
3.
Hurault de Ligny B Toupance O Lavaud S Bauwens M Peyronnet P Le Meur Y Ryckelynck JP Jolly D Leroux-Robert C Touchard G 《Transplantation》2000,69(7):1327-1332
BACKGROUND: The theoretical aim of maintenance cyclosporine monotherapy (mCsA) after kidney transplantation is to reduce the incidence of the metabolic complications of corticosteroids and to minimize the adverse effects of excessive long-term immunosuppression. This study was performed in low-immunological-risk cadaveric kidney transplant recipients to evaluate the risks and benefits of mCsA and the long-term graft survival, and to determine the factors predicting success of this policy. METHODS: The multicenter retrospective study was conducted in 329 Caucasian patients receiving mCsA out of 728 first cadaveric kidney transplant recipients. The inclusion criteria were: HLA antibodies < or =25%, serum creatinine <200 micromol/L, and no rejection or only one rejection episode. At the end of the study, we compared the group of patients successfully treated with mCsA (successful group) with those requiring additional immunosuppressive agents (unsuccessful mCsA group). RESULTS: Overall patient and graft survival rates for the 728 first cadaveric graft were 92% and 64%, respectively, at 8 years. Out of 329 patients enrolled in mCsA, 240 were maintained on this treatment and 89 were withdrawn (3 deaths, 18 graft losses, 68 functional grafts). The 8-year graft survival in the 329 enrolled mCsA patients was 84%, 95% in the successful mCsA group, and 70% in the unsuccessful mCsA group. Multivariate analysis showed that the factors predicting success of mCsA were: donor age <40 years (P = 0.001), serum creatinine at mCsA initiation <125 micromol/L (P = 0.02), no rejection episode before mCsA initiation (P = 0.005), and glomerulopathy as the primary renal disease (P = 0.001). CONCLUSION: Numerous kidney transplant recipients with a low immunological risk and good and stable renal function may benefit from discontinuation of prednisone and azathioprine in order to reduce the complications related to these drugs. This therapeutic approach had no adverse impact on the overall long-term graft survival for "low risk" and successful patients. 相似文献
4.
I. Annesi‐Maesano C. Zhou N. Baïz S. Banerjee D. Andr Charpin D. Caillaud F. de Blay C. Raherison F. Lavaud 《Allergy》2013,68(11):1471-1474
We investigated the relationships of behavioural problems as assessed using the standardized Strengths and Difficulties Questionnaire (SDQ) to asthma in view of improving asthma management. Six thousand eight hundred and eighty children (mean age 10.4 years, male: 49%) were recruited in the French 6 Cities Study. Children with abnormal or borderline emotional symptoms (internalizing problems) or conduct problems (externalizing problems) were more asthmatic than others (P < 0.01). Compared to being normal, abnormal emotional symptoms or conduct problems were found to be related to mild‐to‐moderate persistent asthma (logistic model adjusted odds ratio = 1.55 (95% CI = 1.26–1.90) and 1.42 (95% CI = 1.17–1.71), respectively) and to early‐onset asthma (Cox's model Adjusted Hazard Risk = 1.60 (95% CI = 1.27–2.01) and 1.34 (95% CI = 1.05–1.70). Borderline conduct problems were found to be negatively related to parents' knowledge on how to prevent asthma attacks, compared to normal conduct problems [adjusted OR = 0.51 (95% CI = 0.31–0.85)]. Further data are needed to better understand the involvement of behavioural problems in childhood asthma according to phenotypes. 相似文献
5.
Roseline Porignaux Vincent Vuiblet Coralie Barbe Yohan Nguyen Sylvie Lavaud Olivier Toupance Laurent Andréoletti Philippe Rieu Nicolas Lévêque 《Journal of medical virology》2013,85(6):1115-1121
Described for the first time in 1986, Parvovirus B19 (B19V) infection in kidney transplant recipients remains little‐known and probably underestimated. The aims of this study were to establish B19V infection frequency during the first year after kidney transplant and to determine predisposing factors and manifestations of the infection in renal transplant recipients. Sixty consecutive adult patients, transplanted less than a year before, were included in this study. B19V and other opportunistic viral infections were detected retrospectively in plasma samples collected every 15 days during the first 3 months and every month from 3 months to 1 year following the kidney transplant. Demographic characteristics, immunosuppressive treatment and biological findings were recorded on each sampling date. Six patients (10%) presented B19V viremia, while eight CMV (13.3%), seven EBV (11.7%), five HHV‐6 (8.3%), five BKV (8.3%), and two adenovirus (3.3%) infections were detected. The mean value of B19V viral load was 149 UI/ml. B19V infections were either reactivation or reinfection due to genotype two in five cases, while one case of primary infection with genotype 1 was observed. Neither risk factors nor biological consequences of B19V infection have been identified. These results rank B19V third among opportunistic viral infections occurring during the first year after a kidney transplant. With regard to this high incidence, and even if the risk factors and biological consequences of the infection should be assessed in larger studies, the question of systematic screening and follow‐up of B19V infection in kidney transplant recipients is relevant. J. Med. Virol. 85: 1115–1121, 2013. © 2013 Wiley Periodicals, Inc. 相似文献
6.
7.
Charles Dzviga Catherine Matevi Philippe Bonniaud Fran?ois Lavaud Bruno Girodet Joelle Birnbaum Claude Lambert the Interest Group on Insect Venom Hypersensitivity Allergy from the French Society of Allergology French Federation of Continuous Medical Education in Allergology 《Archives of Medical Science》2016,12(1):150-155
Introduction
Venom immunotherapy (VIT) is the only efficient prevention for sting-induced anaphylaxis, but its application is not without risks and needs precautions and standardization. European guidelines were proposed in 2005, but recent practice surveys and more recent knowledge raise the need for an update. The aim of this study was to analyze VIT practices in France, based on previous surveys in Europe but also extended to outcome event management.Material and methods
A paper questionnaire was sent widely to persons involved in venom treatment.Results
Eighty-six responses could be included from physicians actively involved in VIT induction evenly distributed in France. The survey shows that VIT was engaged from grade III down to grade I reactions, starting preferentially with the ultra-rush protocol. Premedication was used by 42% only and risks induced by co-treatment with β-blockers were well known but not with angiotensin-converting enzyme inhibitors. However, side effects were very variably managed from arrest to enhancement in doses, time-delay or duration. Similarly, we observed a large discrepancy in treatment evaluation (skin tests, biology, timing and interpretation), decision making for treatment termination (when and how long to be prolonged) and post-treatment follow-up (adrenaline kit, event record) as well as procedures in case of late relapse (new induction, different doses).Conclusions
Our study shows that most recommendations were fully or partially followed and may need reminding, but many points need to be completed or updated with new tools and knowledge acquired during the last 10 years. 相似文献8.
Amra Simic MA Pernelle K. Schøndorff MSc Tobias Stumpe BSc Matthias Heschel PhD Werner Regittnig PhD Tina Pöttler Daniela Ninaus MSc Thomas Augustin PhD Andrea Groselj-Strele PhD Thomas R. Pieber MD Julia K. Mader MD 《Diabetes, obesity & metabolism》2021,23(6):1402-1408
Maintaining good glycaemic control with the same infusion set for longer than 3 days may improve the quality of life of insulin pump users. The aim of the current study was to assess the efficacy and safety of the novel, extended-wear infusion set over 7 days of wear in adults with type 1 diabetes. Sixteen participants completed three identical 8-hour euglycaemic clamp experiments on Days 1, 4 and 7 of infusion set wear. Between the experiments, the participants were discharged home for routine diabetes management while wearing the same extended-wear infusion set throughout the study. Time to reach the maximum glucose infusion rate (TGIRmax) on Day 7 was reduced by 67% compared with Day 1 (p < .001). The corresponding area under the glucose infusion rate curve (AUCGIR) was comparable for the first 2 h of the clamp (p = .891) but decreased by 28% over time (p < .008). While the extent of insulin absorption decreased with prolonged wear, it was accompanied by an increase in insulin absorption rate. The infusion set survival rate was 100% without leakages, occlusion alarms, severe hypoglycaemia or ketoacidosis. The extended-wear infusion set proved safe and effective during prolonged wear in real-life conditions. 相似文献
9.
Rayhan A. Lal MD Liana Hsu BS Jian Zhang MD Pernelle K. Schøndorff MS Matthias Heschel PhD Bruce Buckingham MD 《Diabetes, obesity & metabolism》2021,23(8):1973-1977
Current insulin infusion sets are approved for only 2-3 days. The novel ConvaTec infusion set with Lantern technology is designed to extend infusion set wear time. The goal of this pilot study was to evaluate the duration of wear for this set. This was a pilot safety study in adults with type 1 diabetes using tethered insulin pumps. Participants inserted the set and wore it for 10 days or until failure. Among 24 participants, two were excluded. Forty-five per cent of the sets lasted 10 days. Median wear time was 9.1 (7.1, 10.0) days. Among 12 premature failures, six (50%) involved adhesive failures, four (33%) hyperglycaemia unresponsive to correction, one (8%) hyperglycaemia with ketones and one (8%) infection. Average CGM glucose per day of infusion set wear showed a statistically significant increase over time, while total daily insulin over the same period did not change. In this pilot study, the duration of wear for the novel infusion set exceeded previously reported commercial sets (P < .001). This extended wear technology may eventually allow for a combined glucose sensor and infusion set. 相似文献
10.